Trial NCT04450004
Publication Ward B, medRxiv, 2020
Primary outcome on the report: Adverse events. The primary immunological outcomes were neutralizing antibody (NAb) responses measured using a VSV pseudovirion assay (Nexelis Inc, Laval, QC) and IFNkƴ and IL-4 cellular responses measured by ELISpot at D0, 21 and 42.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.